Symbol="ALVR"
AssetType="Common Stock"
Name="AllovirÂ Inc"
Description="Allovir, Inc., a clinical-stage cell therapy company, is dedicated to the research and development of ready-to-use, multi-virus-specific allogeneic T-cell therapies (TSVs) to prevent and treat devastating virus-associated diseases. The company is headquartered in Cambridge, Massachusetts."
CIK="1754068"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="139 MAIN STREET, SUITE 500, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="354395000"
EBITDA="-170896992"
PERatio="None"
PEGRatio="None"
BookValue="2.156"
DividendPerShare="0"
DividendYield="0"
EPS="-1.78"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.451"
ReturnOnEquityTTM="-0.862"
RevenueTTM="0"
GrossProfitTTM="165000"
DilutedEPSTTM="-1.78"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="21.67"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="2.465"
EVToRevenue="-"
EVToEBITDA="-2.054"
Beta="0.639"
num_52WeekHigh="10.29"
num_52WeekLow="2.85"
num_50DayMovingAverage="4.021"
num_200DayMovingAverage="5.44"
SharesOutstanding="113588000"
DividendDate="None"
ExDividendDate="None"
symbol="ALVR"
open="3.16"
high="3.16"
low="2.85"
price="2.87"
volume="773693.00"
latest_trading_day="2023-07-27"
previous_close="3.12"
change="-0.25"
change_percent="-8.0128%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="89"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="11"
Volume_recent_avg="499682"
Change_recent_avg="-0.02"
Delta_recent_avg="0.38"
Variance_recent_avg="0.19"
Change_ratio_recent_avg="-0.51"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="11"
Aroon_momentum_negative="89"
image_negative_thumbnail_id_1="1159"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0193.jpeg"
image_negative_thumbnail_id_2="509"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0096.jpeg"
image_neutral_thumbnail_id_1="566"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0033.jpeg"
image_neutral_thumbnail_id_2="577"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0022.jpeg"
image_positive_thumbnail_id_1="687"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0021.jpeg"
image_positive_thumbnail_id_2="615"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0093.jpeg"
image_professor_thumbnail_id_1="1199"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0033.jpeg"
image_professor_thumbnail_id_2="1168"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0002.jpeg"
